<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94113">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01938755</url>
  </required_header>
  <id_info>
    <org_study_id>odu52</org_study_id>
    <nct_id>NCT01938755</nct_id>
  </id_info>
  <brief_title>Hyperbaric Levobupivacaine for Spinal Anaesthesia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>T.C. ORDU ÜNİVERSİTESİ</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>T.C. ORDU ÜNİVERSİTESİ</source>
  <oversight_info>
    <authority>Harran University, Medical Faculty, Ethics Committee: TURKEY</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal anaesthesia also called spinal block or sub-arachnoid block (SAB), is a form of
      regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space,
      generally through a fine needle.

      There is no generic hyperbaric form of levobupivacaine currently available so we aimed in
      this study that to find the appropriate concentration of the levobupivacaine which achieves
      unilateral spinal anesthesia. The potential benefits of this type of anesthesia are less
      motor blockade and urinary retention, decrease in hospital stay. Therefore, it seems to be
      suitable for outpatient anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>degree of motor blockade</measure>
    <time_frame>until dissolve of motor blockade</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>This Study Was Focused on Selective Spinal Anesthesia for Lower Extremity Surgery in Order to Achieve Early Mobilization and to Shorten Hospital Stay.</condition>
  <arm_group>
    <arm_group_label>levobupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group that was administered levobupivacaine plus 60/80/100 mg dextrose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levobupivacaine</intervention_name>
    <description>levobupivacaine plus 60 mg dextrose</description>
    <arm_group_label>levobupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levobupivacaine</intervention_name>
    <description>levobupivacaine plus 80 mg dextrose</description>
    <arm_group_label>levobupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levobupivacaine</intervention_name>
    <description>levobupivacaine plus 100 mg dextrose</description>
    <arm_group_label>levobupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Approval to participate in the study and spinal anesthesia

          -  American society of anesthesia (ASA) I,II physical status

          -  Scheduled for lower extremity surgery

        Exclusion Criteria:

          -  Refuse to participate in the study

          -  American society of anesthesia (ASA)III, IV physical status

          -  Hypersensitivity to local anesthetics

          -  Emergency surgery

          -  Chronic pain treatment

          -  Peripheral neuropathy

          -  Severe systemic disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anestesia and Reanimation Dept.; Ordu University Education and Research Hospital</name>
      <address>
        <city>Ordu</city>
        <zip>52100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>September 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>T.C. ORDU ÜNİVERSİTESİ</investigator_affiliation>
    <investigator_full_name>özgür yağan</investigator_full_name>
    <investigator_title>Özgür Yağan</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
